222 related articles for article (PubMed ID: 33733372)
1. Pharmacometrics-Based Considerations for the Design of a Pharmacogenomic Clinical Trial Assessing Irinotecan Safety.
Minichmayr IK; Karlsson MO; Jönsson S
Pharm Res; 2021 Apr; 38(4):593-605. PubMed ID: 33733372
[TBL] [Abstract][Full Text] [Related]
2. Population pharmacokinetics of liposomal irinotecan in patients with cancer and exposure-safety analyses in patients with metastatic pancreatic cancer.
Brendel K; Bekaii-Saab T; Boland PM; Dayyani F; Dean A; Macarulla T; Maxwell F; Mody K; Pedret-Dunn A; Wainberg ZA; Zhang B
CPT Pharmacometrics Syst Pharmacol; 2021 Dec; 10(12):1550-1563. PubMed ID: 34750990
[TBL] [Abstract][Full Text] [Related]
3. Pharmacogenetic clinical randomised phase II trial to evaluate the efficacy and safety of FOLFIRI with high-dose irinotecan (HD-FOLFIRI) in metastatic colorectal cancer patients according to their UGT1A 1 genotype.
Páez D; Tobeña M; Fernández-Plana J; Sebio A; Virgili AC; Cirera L; Barnadas A; Riera P; Sullivan I; Salazar J
Br J Cancer; 2019 Jan; 120(2):190-195. PubMed ID: 30585257
[TBL] [Abstract][Full Text] [Related]
4. Association of UGT1A1*6 polymorphism with irinotecan-based chemotherapy reaction in colorectal cancer patients: a systematic review and a meta-analysis.
Zhu X; Ma R; Ma X; Yang G
Biosci Rep; 2020 Oct; 40(10):. PubMed ID: 32936306
[TBL] [Abstract][Full Text] [Related]
5. Recommendations from the EGAPP Working Group: can UGT1A1 genotyping reduce morbidity and mortality in patients with metastatic colorectal cancer treated with irinotecan?
Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group
Genet Med; 2009 Jan; 11(1):15-20. PubMed ID: 19125128
[TBL] [Abstract][Full Text] [Related]
6. Pharmacogenetic impact of UGT1A1 polymorphisms on pulmonary neuroendocrine tumours treated with metronomic irinotecan-based chemotherapy in Chinese populations.
Ma X; Han S; Liu Y; Liu JT; Fang J; Zhang YH
J Pharm Pharmacol; 2020 Nov; 72(11):1528-1535. PubMed ID: 32737884
[TBL] [Abstract][Full Text] [Related]
7. Integration of DNA sequencing with population pharmacokinetics to improve the prediction of irinotecan exposure in cancer patients.
Karas S; Etheridge AS; Nickerson DA; Cox NJ; Mohlke KL; Cecchin E; Toffoli G; Mathijssen RHJ; Forrest A; Bies RR; Innocenti F
Br J Cancer; 2022 Mar; 126(4):640-651. PubMed ID: 34703007
[TBL] [Abstract][Full Text] [Related]
8. Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics.
Innocenti F; Kroetz DL; Schuetz E; Dolan ME; Ramírez J; Relling M; Chen P; Das S; Rosner GL; Ratain MJ
J Clin Oncol; 2009 Jun; 27(16):2604-14. PubMed ID: 19349540
[TBL] [Abstract][Full Text] [Related]
9. Model-Based Prediction of Irinotecan-Induced Grade 4 Neutropenia in Cancer Patients: Influence of Incorporating Germline Genetic Factors in the Model.
Karas S; Mathijssen RHJ; van Schaik RHN; Forrest A; Wiltshire T; Bies RR; Innocenti F
Clin Pharmacol Ther; 2024 May; 115(5):1162-1174. PubMed ID: 38344867
[TBL] [Abstract][Full Text] [Related]
10. Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan.
Innocenti F; Undevia SD; Iyer L; Chen PX; Das S; Kocherginsky M; Karrison T; Janisch L; Ramírez J; Rudin CM; Vokes EE; Ratain MJ
J Clin Oncol; 2004 Apr; 22(8):1382-8. PubMed ID: 15007088
[TBL] [Abstract][Full Text] [Related]
11. Dose-dependent association between UGT1A1*28 genotype and irinotecan-induced neutropenia: low doses also increase risk.
Hu ZY; Yu Q; Pei Q; Guo C
Clin Cancer Res; 2010 Aug; 16(15):3832-42. PubMed ID: 20562211
[TBL] [Abstract][Full Text] [Related]
12. Irinotecan and uridine diphosphate glucuronosyltransferase 1A1 pharmacogenetics: to test or not to test, that is the question.
Deeken JF; Slack R; Marshall JL
Cancer; 2008 Oct; 113(7):1502-10. PubMed ID: 18720361
[TBL] [Abstract][Full Text] [Related]
13. UGT1A1 genotype-guided dosing of irinotecan: A prospective safety and cost analysis in poor metaboliser patients.
Hulshof EC; de With M; de Man FM; Creemers GJ; Deiman BALM; Swen JJ; Houterman S; Koolen SLW; Bins S; Thijs AMJ; Laven MMJ; Hövels AM; Luelmo SAC; Houtsma D; Shulman K; McLeod HL; van Schaik RHN; Guchelaar HJ; Mathijssen RHJ; Gelderblom H; Deenen MJ
Eur J Cancer; 2022 Feb; 162():148-157. PubMed ID: 34998046
[TBL] [Abstract][Full Text] [Related]
14. Clinical and pharmacogenetic determinants of 5-fluorouracyl/leucovorin/irinotecan toxicity: Results of the PETACC-3 trial.
Tejpar S; Yan P; Piessevaux H; Dietrich D; Brauchli P; Klingbiel D; Fiocca R; Delorenzi M; Bosman F; Roth AD
Eur J Cancer; 2018 Aug; 99():66-77. PubMed ID: 29909091
[TBL] [Abstract][Full Text] [Related]
15. Elucidating the role of pharmacogenetics in irinotecan efficacy and adverse events in metastatic colorectal cancer patients.
Riera P; Páez D
Expert Opin Drug Metab Toxicol; 2021 Oct; 17(10):1157-1163. PubMed ID: 34486919
[TBL] [Abstract][Full Text] [Related]
16. Irinotecan dose reduction in metastatic colorectal cancer patients with homozygous
Tsai HL; Chen PJ; Chen YC; Li CC; Chang TK; Su WC; Yin TC; Huang CW; Wang JY
J Int Med Res; 2022 Jul; 50(7):3000605221110697. PubMed ID: 35822291
[TBL] [Abstract][Full Text] [Related]
17.
Peeters SL; Deenen MJ; Thijs AM; Hulshof EC; Mathijssen RH; Gelderblom H; Guchelaar HJ; Swen JJ
Pharmacogenomics; 2023 Jun; 24(8):435-439. PubMed ID: 37470120
[TBL] [Abstract][Full Text] [Related]
18. An internally and externally validated nomogram for predicting the risk of irinotecan-induced severe neutropenia in advanced colorectal cancer patients.
Ichikawa W; Uehara K; Minamimura K; Tanaka C; Takii Y; Miyauchi H; Sadahiro S; Fujita K; Moriwaki T; Nakamura M; Takahashi T; Tsuji A; Shinozaki K; Morita S; Ando Y; Okutani Y; Sugihara M; Sugiyama T; Ohashi Y; Sakata Y
Br J Cancer; 2015 May; 112(10):1709-16. PubMed ID: 25880011
[TBL] [Abstract][Full Text] [Related]
19. UGT1A1*6 polymorphisms are correlated with irinotecan-induced neutropenia: a systematic review and meta-analysis.
Zhang X; Yin JF; Zhang J; Kong SJ; Zhang HY; Chen XM
Cancer Chemother Pharmacol; 2017 Jul; 80(1):135-149. PubMed ID: 28585035
[TBL] [Abstract][Full Text] [Related]
20. Pharmacogenetics and irinotecan therapy.
Hahn KK; Wolff JJ; Kolesar JM
Am J Health Syst Pharm; 2006 Nov; 63(22):2211-7. PubMed ID: 17090741
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
